Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SARUPANC phase II trial of saruparib first-line monotherapy in metastatic homologous recombination-deficient pancreatic cancer
2024-516558-24-00Phase 2Completed
- Sponsor
- Centre Léon Bérard
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of saruparib in pancreatic adenocarcinoma (PDAC), sponsored by Centre Léon Bérard. Primary endpoint: Objective response rate at Week 16. Started Jan 2026; status: completed.
02
Drugs
saruparib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-516558-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516558-24-00.